A cohort study comparing serum IL-6 levels in 26 NMOSD patients during relapse and remission showed that IL-6 levels were significantly elevated in NMOSD patients during relapse compared with remission (n = 19, 8.39 ± 10.84 pg/ml vs. n = 19, 2.02 ± 2.27 pg/ml, p = 0.001) and in HCC patients (n = 16, 1.23 ± 1.18 pg/ml, p < 0.01). This evidence concerns the gene IL6 and hepatocellular carcinoma.